Therefore, our research identifies DLGAP5 as a potential biomarker for predicting chemotherapy response and proposes targeting the DLGAP5/MYC/glycolysis metabolic pathway as a strategy to overcome GEM resistance in BLCA. Here, DLGAP5 is linked to bladder transitional cell carcinoma.